IL286716A - An inhibitor containing an antibody to the anti-il-6 receptor to inhibit the deterioration of bbb function - Google Patents
An inhibitor containing an antibody to the anti-il-6 receptor to inhibit the deterioration of bbb functionInfo
- Publication number
- IL286716A IL286716A IL286716A IL28671621A IL286716A IL 286716 A IL286716 A IL 286716A IL 286716 A IL286716 A IL 286716A IL 28671621 A IL28671621 A IL 28671621A IL 286716 A IL286716 A IL 286716A
- Authority
- IL
- Israel
- Prior art keywords
- receptor antibody
- containing inhibitor
- inhibiting deterioration
- bbb function
- bbb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019068693 | 2019-03-29 | ||
| PCT/JP2020/005965 WO2020202839A1 (ja) | 2019-03-29 | 2020-02-17 | 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286716A true IL286716A (en) | 2021-12-01 |
Family
ID=72667972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286716A IL286716A (en) | 2019-03-29 | 2021-09-26 | An inhibitor containing an antibody to the anti-il-6 receptor to inhibit the deterioration of bbb function |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220220210A1 (https=) |
| EP (1) | EP3949989A4 (https=) |
| JP (2) | JPWO2020202839A1 (https=) |
| KR (1) | KR20210144795A (https=) |
| CN (1) | CN113660951A (https=) |
| AU (1) | AU2020255449A1 (https=) |
| BR (1) | BR112021017702A2 (https=) |
| CA (1) | CA3133610A1 (https=) |
| IL (1) | IL286716A (https=) |
| MX (1) | MX2021011464A (https=) |
| TW (1) | TWI859192B (https=) |
| WO (1) | WO2020202839A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| EP4413998A4 (en) * | 2021-10-08 | 2026-02-25 | Chugai Pharmaceutical Co Ltd | METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION |
| KR20240145472A (ko) * | 2022-01-19 | 2024-10-07 | 추가이 세이야쿠 가부시키가이샤 | 사트랄리주맙을 사용하는 자기면역 뇌염의 치료 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| KR101680906B1 (ko) * | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| SI2315780T1 (sl) * | 2008-07-17 | 2015-11-30 | Novartis Ag | Sestavki in postopki uporabe za terapevtska protitelesa |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JP4809930B2 (ja) | 2009-03-19 | 2011-11-09 | 中外製薬株式会社 | 関節リウマチ治療剤 |
| WO2010106812A1 (en) | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| AU2012322721B2 (en) * | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| EP3185004A4 (en) * | 2014-08-20 | 2018-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| US11447752B2 (en) | 2016-04-15 | 2022-09-20 | Yamaguchi University | In vitro model for blood-brain barrier and method for producing in vitro model for blood-brain barrier |
-
2020
- 2020-02-17 US US17/437,448 patent/US20220220210A1/en active Pending
- 2020-02-17 CA CA3133610A patent/CA3133610A1/en active Pending
- 2020-02-17 CN CN202080025917.0A patent/CN113660951A/zh active Pending
- 2020-02-17 BR BR112021017702A patent/BR112021017702A2/pt unknown
- 2020-02-17 KR KR1020217034263A patent/KR20210144795A/ko active Pending
- 2020-02-17 EP EP20783563.8A patent/EP3949989A4/en active Pending
- 2020-02-17 JP JP2021511193A patent/JPWO2020202839A1/ja active Pending
- 2020-02-17 MX MX2021011464A patent/MX2021011464A/es unknown
- 2020-02-17 AU AU2020255449A patent/AU2020255449A1/en active Pending
- 2020-02-17 WO PCT/JP2020/005965 patent/WO2020202839A1/ja not_active Ceased
- 2020-02-17 TW TW109105023A patent/TWI859192B/zh active
-
2021
- 2021-09-26 IL IL286716A patent/IL286716A/en unknown
-
2024
- 2024-04-25 JP JP2024071421A patent/JP2024102154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202102540A (zh) | 2021-01-16 |
| TWI859192B (zh) | 2024-10-21 |
| WO2020202839A1 (ja) | 2020-10-08 |
| EP3949989A4 (en) | 2022-12-14 |
| JP2024102154A (ja) | 2024-07-30 |
| CN113660951A (zh) | 2021-11-16 |
| AU2020255449A1 (en) | 2021-10-07 |
| JPWO2020202839A1 (https=) | 2020-10-08 |
| BR112021017702A2 (pt) | 2021-11-16 |
| CA3133610A1 (en) | 2020-10-08 |
| MX2021011464A (es) | 2021-10-22 |
| EP3949989A1 (en) | 2022-02-09 |
| US20220220210A1 (en) | 2022-07-14 |
| KR20210144795A (ko) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286716A (en) | An inhibitor containing an antibody to the anti-il-6 receptor to inhibit the deterioration of bbb function | |
| IL313281B1 (en) | Prmt5 inhibitors that cooperate with mta | |
| ZA202203770B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| HUE061482T2 (hu) | Szintézismódszer | |
| PT3814341T (pt) | Inibidores de recetor erbb | |
| IL304110A (en) | Keap1–nrf2 protein–protein interaction inhibitors | |
| IL285697A (en) | Combined stress response pathway inhibitors | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL288747A (en) | Inhibitors of an integrated stress response pathway | |
| IL290087A (en) | inhibitory substances | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL286708A (en) | Inhibitors of the n-terminal domain of the androgen receptor | |
| IL289214A (en) | Crystalline forms of plasma kallikrein inhibitors | |
| GB201905328D0 (en) | Inhibitor compounds | |
| IL288292A (en) | Oxathiazine compounds for gapdh inhibition | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| DK3966480T3 (da) | Enspakspatron til sanitetsarmaturer | |
| GB201909228D0 (en) | Screen for inhibitors | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| IL291368A (en) | Inhibits expression of methadherin | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| GB201915908D0 (en) | Crystalline forms of entrectinib | |
| GB201910664D0 (en) | Novel forms of compound | |
| GB201905318D0 (en) | Inhibitor compounds |